SCHEMBL13615209

SCHEMBL13615209

CC(C)(C)c1ccc(NS(=O)(=O)c2c(Cl)cccc2Cl)cc1F

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.50
LMNA P02545 4/20 0.50
ATM Q13315 1/20 0.50
MAPT P10636 3/20 0.46
MEN1 O00255 3/20 0.46
KMT2A Q03164 3/20 0.46
PKM P14618 3/20 0.46
SLC22A12 Q96S37 4/20 0.45
MCL1 Q07820 1/20 0.45
GAA P10253 1/20 0.45
THRB P10828 2/20 0.41
HTT P42858 1/20 0.41
CYP1A2 P05177 1/20 0.41
CYP3A4 P08684 1/20 0.41
MAPK1 P28482 1/20 0.41
CYP2C19 P33261 1/20 0.41
CDK1 P06493 1/20 0.41
CCNB1 P14635 1/20 0.41
CCNA2 P20248 1/20 0.41
CCND1 P24385 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13615274 0.87 PTGES2 (0.52) ALDH1A1LMNAMEN1KMT2ASLC22A12
SCHEMBL13615141 0.86 SLC22A12 (0.54) ALDH1A1LMNAMAPTMEN1KMT2A
SCHEMBL13615132 0.85 ALDH1A1 (0.57) ALDH1A1LMNAATMMAPTMEN1
SCHEMBL13615211 0.82 PKM (0.60) ALDH1A1LMNAMAPTMEN1KMT2A
SCHEMBL13615225 0.80 PPARG (0.55) LMNAMAPTMEN1KMT2ASLC22A12
SCHEMBL13615181 0.80 ALDH1A1 (0.56) ALDH1A1LMNAMAPTMEN1KMT2A
SCHEMBL13615216 0.80 BRD4 (0.52) SLC22A12MCL1THRBHPGDSMN1; SMN2
SCHEMBL13629427 0.80 ALDH1A1 (0.54) ALDH1A1LMNAATMMAPTMEN1
SCHEMBL13615120 0.80 CES1 (0.57) ALDH1A1LMNAMAPTMEN1KMT2A
SCHEMBL13615171 0.80 MEN1 (0.48) ALDH1A1LMNAMAPTMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090275593-A1 3 Substituted N-(aryl- or heteroaryl)-pyrazolo[1,5-a]pyrimidines as Kinase Inhibitors NOVARTIS AG 2009-11-05 US disclosed
US-20090118277-A1 3 Unsubstituted N-(aryl- or heteroaryl)-pyrazolo[1,5-a]pyrimidines as Kinase Inhibitors NOVARTIS AG 2009-05-07 US disclosed
US-20090118277-A1 3 Unsubstituted N-(aryl- or heteroaryl)-pyrazolo[1,5-a]pyrimidines as Kinase Inhibitors NOVARTIS AG 2009-05-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090118277-A1 3 Unsubstituted N-(aryl- or heteroaryl)-pyrazolo[1,5-a]pyrimidines as Kinase Inhibitors TIE1, TEK, MATK ALDH1A1 2057/4885LMNA 2891/4885ATM 564/4885
US-20090275593-A1 3 Substituted N-(aryl- or heteroaryl)-pyrazolo[1,5-a]pyrimidines as Kinase Inhibitors TIE1, TEK, MATK ALDH1A1 2121/4885LMNA 2608/4885ATM 465/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.